Dr. Paika Podcast

#GLP1 #Menopause #Tirzepatide #Semaglutide #WeightLoss

Not losing weight on a GLP-1 after menopause? You’re not imagining it, but your body isn’t broken and the medication hasn’t stopped working. In this video, I’m Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. I break down what the research really shows about GLP-1s like tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) after menopause.

You’ll learn what menopause does to fat, muscle and metabolism, and how much weight women actually lose at each stage of menopause in the clinical trials. I’ll show you why real-world results can lag, what the newest hormone therapy studies show and why they don’t prove cause and effect, and how to protect your muscle and bones. I’ll also walk you through the 5-step plan I use with my midlife patients.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

 TIMESTAMPS
0:00 Why weight loss feels harder after menopause
1:56 What menopause does to your body
4:15 Do GLP-1s still work after menopause?
7:12 Why it feels harder in real life
9:06 Hormone therapy and GLP-1s: what the data shows
11:21 Free GLP-1 Diet Cookbook
11:44 Protecting your muscle and bones
13:42 GLP-1 Masterclass
14:12 The 5-step midlife GLP-1 plan
15:35 A real viewer example
16:41 Final thoughts

📚 REFERENCES
Greendale GA, et al. Changes in body composition and weight during the menopause transition (SWAN). JCI Insight. 2019;4(5):e124865.
Lovejoy JC, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32(6):949-958.
Pontzer H, et al. Daily energy expenditure through the human life course. Science. 2021;373(6556):808-812.
Karppinen JE, et al. Age but not menopausal status is linked to lower resting energy expenditure. J Clin Endocrinol Metab. 2023;108(11):2789-2797.
Thomson ZO, et al. Weight loss outcomes in premenopausal versus postmenopausal women during behavioral weight loss interventions. Menopause. 2021;28(3):337-346.
Tchang BG, et al. Body weight reduction in women treated with tirzepatide by reproductive stage (SURMOUNT post hoc). Obesity. 2025;33:851-860.
García-Pérez LE, et al. Tirzepatide weight reduction by sex: SURMOUNT-1 to -4 post hoc. Presented at EASD 2024.
Castaneda R, et al. Sex, not age, predicts weight loss outcomes with tirzepatide. Obesity. 2026;34(Suppl 2):132-145.
Huvinen E, et al. Body weight loss with semaglutide 7.2 mg is independent of menopausal status (STEP UP post hoc). Presented at the European Congress on Obesity, 2026.
Castaneda R, et al. Impact of reproductive stage and menopausal hormone therapy on weight loss outcomes with tirzepatide. Presented at The Menopause Society Annual Meeting, 2025.
Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. 2010;153(7):435-441.
Hurtado MD, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31:266.
Castaneda R, et al. Menopause hormone therapy and tirzepatide-associated weight loss in postmenopausal women. Lancet Obstet Gynaecol Womens Health. 2026;2(2):e118-e128.
Hurtado MD, et al. Semaglutide reduces body weight regardless of menopause status (STEP and OASIS 4 post hoc). Presented at ObesityWeek, 2025.
Papadakis GE, et al. Menopausal hormone therapy is associated with reduced total and visceral adiposity (OsteoLaus). J Clin Endocrinol Metab. 2018;103(5):1948-1957.
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
Look M, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025.
Jensen SBK, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Netw Open. 2024;7(6):e2416775.
Watson SL, et al. High-intensity resistance and impact training in postmenopausal women with low bone mass (LIFTMOR). J Bone Miner Res. 2018;33(2):211-220.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Ozempic #Wegovy #Zepbound #WeightLoss

Why GLP-1 Medications Cause Extreme Fatigue (And How to Fix Low Energy)

Are you exhausted on Ozempic, Wegovy, Mounjaro, or Zepbound? You’re not imagining it. Fatigue is listed in the prescribing information, and it’s one of the most common complaints I see in the comments.

In this video, I’m Dr. Mohammed Paika, an internal medicine and obesity medicine physician. I break down the 4 biological reasons GLP-1 medications can leave you drained: unintentional undereating, quiet dehydration, the drug’s effects on the brain, and nutrient deficiencies like low iron and B12. Then I walk you through 4 practical fixes: a calorie and protein floor, a hydration plan that goes beyond plain water, the blood work to ask your doctor for, and how to talk to your prescriber about dose and titration. I finish with the warning signs that mean you need to be seen right away.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

This video is for education only and is not personal medical advice. Talk to your own clinician before changing your diet, fluids, supplements, or medication.

TIMESTAMPS
0:00 Why you feel exhausted on a GLP-1
2:00 Who I am and why I made this video
3:09 Is the drug toxic? What the trials show
4:35 Cause #1: Running on empty
7:43 Cause #2: The thirst signal goes quiet
10:35 Cause #3: The drug talks to your brain
12:52 Cause #4: The deficiency nobody tests for
15:27 Fix #1: Set a calorie and protein floor
18:01 Fix #2: Hydrate beyond plain water
19:44 Fix #3: The blood work to ask for
21:10 Fix #4: Slow the dose down, don’t quit
22:36 Red flags: when to get seen urgently

REFERENCES

Wegovy (semaglutide) Prescribing Information. FDA, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
Zepbound (tirzepatide) Prescribing Information. https://uspl.lilly.com/zepbound/zepbound.html; Jastreboff AM, et al. N Engl J Med. 2022;387:205–216 (SURMOUNT-1).
Friedrichsen M, et al. Diabetes Obes Metab. 2021;23:754–762. https://doi.org/10.1111/dom.14280
Prado CM, et al. Lancet Diabetes Endocrinol. 2024;12:785–787. https://doi.org/10.1016/S2213-8587(24)00272-9
Winzeler B, et al. J Clin Invest. 2021;131:e151800. https://jci.org/articles/view/151800
Gutzwiller JP, et al. Digestion. 2006;73:142–150.
Gabery S, et al. JCI Insight. 2020;5:e133429. https://insight.jci.org/articles/view/133429
Butsch WS, et al. Obesity Pillars. 2025;15:100186. https://doi.org/10.1016/j.obpill.2025.100186
Mozaffarian D, et al. Am J Clin Nutr. 2025;122:344–367. https://doi.org/10.1016/j.ajcnut.2025.04.023
Aroda VR, et al. J Clin Endocrinol Metab. 2016;101:1754–1761. https://pmc.ncbi.nlm.nih.gov/articles/PMC4880159
Westerterp-Plantenga MS, et al. J Appl Physiol. 1999;87:391–399. https://pubmed.ncbi.nlm.nih.gov/10409600/
Paika MK. GLP-1 Masterclass; The Weight Equation; GLP-1 Diet Cookbook. https://drmohammedpaika.com

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #GLP1 #Semaglutide #AlcoholUseDisorder #WeightLoss

People on Ozempic and Wegovy are reporting a side effect that isn't on the label: they're losing interest in alcohol. Is it real, or just nausea? As an internal medicine and obesity medicine physician, I work this up like an unexplained finding in a hospital patient. We'll look at the patient reports and real-world data, consider every possible explanation, read the newest trials (including the 2026 Lancet trial), and finish with a practical plan.

In this video you'll learn:
Why GLP-1 drugs may turn down cravings, and what "food noise" really is
What the Lancet, JAMA Psychiatry and earlier trials actually found
Why the first human trial failed, and how it shaped the one that worked
What we still don't know before this becomes a standard treatment
5 safety rules if you drink while on a GLP-1

TIMESTAMPS
0:00 – A strange answer on the admission form
1:44 – What patients are reporting (and what the data shows)
3:20 – Why this matters: the alcohol treatment gap
4:43 – Three possible explanations
7:43 – How GLP-1s act on the brain: the two buttons
10:36 – Protecting your muscle on a GLP-1
11:17 – The 2026 Lancet trial
12:43 – The lab trial: what changed and what didn't
13:53 – The trial that failed, and what it taught us
15:33 – Animal research foundations
16:28 – Would I prescribe it for alcohol today?
18:46 – 5 rules before your next drink on a GLP-1
20:30 – Treatments that already work
21:46 – Final thoughts and resources

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

REFERENCES
Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. Lancet. 2026;407(10540):1687–1698. https://doi.org/10.1016/S0140-6736(26)00305-3
Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395–405.
Klausen MK, et al. Exenatide once weekly for alcohol use disorder. JCI Insight. 2022;7(19):e159863. https://insight.jci.org/articles/view/159863
Lähteenvuo M, et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025;82(1):94–98.
Wang W, Volkow ND, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder. Nat Commun. 2024;15:4548. https://doi.org/10.1038/s41467-024-48780-6
Quddos F, et al. Physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity. Sci Rep. 2025. https://doi.org/10.1038/s41598-025-17927-w
Suchankova P, et al. The GLP-1 receptor as a potential treatment target in alcohol use disorder. Transl Psychiatry. 2015;5:e583. https://www.nature.com/articles/tp201568
Thomsen M, et al. GLP-1 analogs and alcohol intake in vervet monkeys. Psychopharmacology. 2019;236:603–611.
Aranäs C, et al. Semaglutide reduces alcohol intake and relapse-like drinking in rats. eBioMedicine. 2023;93:104642.
Leggio L, et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med. 2023;29:2993–2995.
Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol. 2016;71(8):670–679.
Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374:363–371.
Wilding JPH, et al. Weight regain after withdrawal of semaglutide: STEP 1 extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
Jonas DE, et al. Pharmacotherapy for adults with alcohol use disorders. JAMA. 2014;311(18):1889–1900.
Han B, et al. Use of medications for alcohol use disorder in the US. JAMA Psychiatry. 2021;78(8):922–924.
World Health Organization. Global status report on alcohol and health. 2024.
U.S. Surgeon General. Alcohol and Cancer Risk Advisory. 2025.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Retatrutide #GLP3 #WeightLoss #GLP1 #ObesityMedicine

How long does retatrutide actually stay in your system? Retatrutide, the triple-hormone drug people call "GLP-3" or "reta," has a half-life of about 6 days. That one number explains when side effects hit and why the dose has to climb slowly. It also explains why a short pause before surgery may not be enough, and why the drug lingers for about a month after your last shot.

I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. In this video, I walk you through the 4 clocks retatrutide sets in your body and what the phase 3 trials really show, including up to 30.3% weight loss. You'll learn about the side effects people aren't talking about, like changes in skin sensation and heart rate. I also explain why the "research use only" vials sold online are a serious risk. Retatrutide is not FDA-approved. The regulated routes are a clinical trial, Lilly's limited early access program (through your doctor) or waiting for approval.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

TIMESTAMPS
00:00 The ER patient who "wasn't taking anything"
01:42 What retatrutide is: 3 signals instead of 2
02:34 What the trials show
03:20 Is retatrutide FDA-approved? How people get it legally
04:02 Retatrutide's half-life: about 6 days
04:27 Why it lasts so long
05:07 Clock 1: the 7-day clock and side effects
06:13 The new side effect: dysesthesia
06:52 Heart rate and heart safety
07:30 Missed dose: there's no official rule
08:11 Clock 2: building up to steady state
08:50 How the trials raised the dose
09:43 Why vials make dosing dangerous
10:34 Clock 3: how long retatrutide stays in your system
11:31 What changes how fast you clear it
12:26 Why side effects don't stop when you stop
12:57 Surgery, endoscopy and sedation
13:42 Pregnancy and contraception
14:15 The vial problem: "research use only"
14:57 What's really in the vial?
15:41 My position as your doctor
17:11 Clock 4: what happens when you stop
17:37 Why your body defends its old weight
18:21 What the stopping data shows
18:55 My own weight-regain story
19:42 Muscle is the real stake
20:31 The plan
21:27 Protecting your muscle on GLP-1s

REFERENCES 
(FULL LIST AVAILABLE ON REQUEST)

Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022;400:1869–1881. https://www.sciencedirect.com/science/article/abs/pii/S0140673622020335
Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Eli Lilly and Company. Retatrutide TRIUMPH-4 phase 3 results. December 11, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
Eli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 results; BLA planned Q1 2027. July 23, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
Sanyal AJ, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. https://www.nature.com/articles/s41591-024-03018-2
Axios. Unapproved obesity drug spawns a black market frenzy. August 24, 2026. https://www.axios.com/2026/08/24/unapproved-obesity-drug-spawns-a-black-market-frenzy
The Partnership for Safe Medicines. The retatrutide black market: patient safety groups warn of growing risks. August 2026. https://www.safemedicines.org/2026/08/reta-groups-warn-understudied-drugs.html
Finnrick. Retatrutide testing results (accessed October 2026). https://www.finnrick.com/products/retatrutide

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #WeightLoss #Ozempic #Mounjaro #ObesityMedicine

Not losing weight on a GLP-1? The problem usually isn't you, and it usually isn't the medication either. It's the variables nobody checked.

I'm Dr. Mohammed Paika, a physician board-certified in Internal Medicine and Obesity Medicine. I've spent about 15 years as a hospitalist, and I'm also a certified personal trainer and nutrition coach. In this video, I walk you through 8 evidence-based reasons the scale can stall on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), plus a bonus. They range from diabetes and insulin resistance to medications that quietly cause weight gain, eating too little, muscle loss, sleep apnea and dose problems. At the end, I share my 4-question test to tell whether your GLP-1 is working, stalling or needs to be changed.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

⏱️ TIMESTAMPS
0:00 Why your GLP-1 isn't working (the 2 a.m. patient)
1:47 Reason 1: Your starting point was different
3:47 Reason 2: Diabetes, insulin resistance and PCOS
5:13 Reason 3: Medications quietly working against you
6:57 Reason 4: You're eating too little, not too much
8:47 Reason 5: The quiet calorie creep
10:07 Free GLP-1 Diet Cookbook
10:33 Reason 6: You're losing muscle, and the scale can't tell you
12:29 Reason 7: The exercise myth, and what works instead
14:06 GLP-1 Masterclass
14:41 Reason 8: Sleep, stress and sleep apnea
15:55 Bonus: Dose, timing, injection site and refills
17:35 The 4-question test: is your GLP-1 working?
19:36 What to watch next

📚 REFERENCES

Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
Davies M, et al. Semaglutide 2.4 mg in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
Garvey WT, et al. Tirzepatide in people with obesity and type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
Look M, et al. Body composition changes with tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025.
Mosenzon O, et al. Clinically relevant weight loss independent of early response to semaglutide 2.4 mg (STEP 4). J Endocr Soc. 2021;5(Suppl 1).
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.
Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.
Lichtman SW, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med. 1992;327:1893-1898.
Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. 2010;153:435-441.
Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24:1612-1619.
LaForgia J, et al. Effects of exercise intensity and duration on excess post-exercise oxygen consumption. J Sports Sci. 2006;24:1247-1264.
Pontzer H, et al. Constrained total energy expenditure and metabolic adaptation to physical activity. Curr Biol. 2016;26:410-417.
Greendale GA, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4:e124865.
Magkos F, et al. Effects of moderate and subsequent progressive weight loss on metabolic function. Cell Metab. 2016;23:591-601.
Wegovy (semaglutide) and Zepbound (tirzepatide) U.S. Prescribing Information.
Paika MK. GLP-1 Masterclass. 2026.
Paika MK. The Weight Equation: A Physician's Guide to the Science and Treatment of Obesity. 2026.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Tirzepatide #Mounjaro #Zepbound #GLP1 #WeightLoss

How long does tirzepatide (Mounjaro, Zepbound) actually stay in your system? It's not 5 days. In this video, I explain tirzepatide's half-life using 4 clocks it sets in your body. Those clocks explain when side effects hit and what to do if you miss a dose. They also explain why a 1-week pause before surgery may not be enough, why the birth control rule is 4 weeks, and how long the drug takes to clear after your last shot.

Then we get to the clock that matters most: what happens after you stop. You'll see what the SURMOUNT-4 trial found about weight regain and why muscle loss is the real risk. I'll also share how I regained 45 pounds when my own structure disappeared, and the 2 paths that protect your results.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

TIMESTAMPS
00:00 Why "it's gone in 5 days" is wrong
01:26 What tirzepatide is and how it works
02:25 Half-life explained
02:59 Why it lasts so long: albumin binding
03:48 Clock 1: the 7-day clock
04:18 Side effects: when they hit and how to ease them
05:47 Why food noise returns at the end of the week
06:14 Missed a dose? The 96-hour rule
07:16 Clock 2: the 4-week clock and steady state
08:06 Why your dose goes up in 2.5 mg steps
09:05 Birth control: the 4-week rule
10:09 Clock 3: how long tirzepatide stays in your system
10:56 What makes clearance faster or slower
12:39 Why severe side effects don't stop when you stop
13:42 Surgery, colonoscopy and sedation
15:07 Pregnancy planning
15:35 Will it show up on a drug test?
16:12 Clock 4: what happens when you stop
16:46 Why your body fights weight loss
17:36 SURMOUNT-4: stopping vs staying on
17:58 My own weight-regain story
18:48 The muscle problem
19:51 The plan: 2 good paths
21:17 Protecting your muscle on GLP-1s

REFERENCES
Eli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. https://pi.lilly.com/us/zepbound-uspi.pdf
Kindel TL, et al. Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period. 2024. https://www.cghjournal.org/article/S1542-3565(24)00910-8/fulltext
American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. June 29, 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative
Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. https://jamanetwork.com/journals/jama/fullarticle/2812936
Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–1604. https://pubmed.ncbi.nlm.nih.gov/22029981/
Eli Lilly and Company. SURMOUNT-1 results published in The New England Journal of Medicine. 2022. https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine
Deacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36:761–765.
Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612–1619. https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21538
Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/39996356/
Paika MK. GLP-1 Masterclass; The Weight Equation; Obesity Medicine in Clinical Practice: High-Yield Guide; The Physician's Physique.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #GLP1 #Wegovy #EyeHealth #obesitymedicine 

Can Ozempic, Wegovy or Mounjaro make you blind? A viewer asked me this, and it deserves an honest, evidence-based answer. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine, with more than 15 years as a hospitalist.

In this video I review every major study on GLP-1 medications and NAION, a rare "stroke" of the optic nerve:

The Mass Eye and Ear study that sparked the headlines
The larger studies from Denmark, Norway and the US
The randomized trials

I also cover what the European Medicines Agency, the UK's MHRA and the American Academy of Ophthalmology concluded, plus the separate issue of diabetic retinopathy. You'll learn the real risk in actual numbers, who is at higher risk, and a 5-step eye-safety plan, including the one warning sign that means you go to the ER the same day.

TIMESTAMPS
0:00 Can GLP-1s make you blind? A viewer's question
0:58 Who I am and why this matters
1:37 What is NAION? The "stroke" of the optic nerve
3:15 How the alarm started: the Mass Eye and Ear study
4:16 What the bigger studies found
6:13 GLP-1 Masterclass
6:51 What regulators and eye specialists concluded
8:44 Putting the risk in perspective
9:28 The other eye issue: diabetic retinopathy
10:41 Free GLP-1 Diet Cookbook
11:01 Who is at higher risk?
12:16 The 5-step eye-safety plan
14:10 What to watch next

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

REFERENCES
StatPearls: Nonarteritic anterior ischemic optic neuropathy. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK559045/
Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 1994;14(1):38-44
Hathaway JT, Shah M, Hathaway DB, et al. Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739
Grauslund J, Abou Taha A, Molander LD, et al. Once-weekly semaglutide doubles the five-year risk of NAION in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024;10:97
Simonsen E, Lund LC, Ernst MT, et al. Use of semaglutide and risk of NAION: a Danish–Norwegian cohort study. Diabetes Obes Metab. 2025;27(6):3094-3103
Hsu AY, et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025. doi:10.1001/jamaophthalmol.2025.0349
Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025;8(8):e2526327
DeParis SW, et al. GLP-1 receptor agonists and the risk of NAION: a consensus statement by NANOS and the American Academy of Ophthalmology. Ophthalmology. 2026;133(8)
NAION risk with semaglutide: what we know so far (includes Chou et al., 18,657 patients). Eye. 2025. https://www.nature.com/articles/s41433-025-03833-y
Liu Z, Raveendran D, Fourlanos S, et al. Rate and risk of NAION with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis. Ophthalmology. 2026;133:589-598
European Medicines Agency (PRAC). NAION a very rare side effect of semaglutide. June 2025. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy
MHRA Drug Safety Update: Semaglutide and risk of NAION. Feb 5, 2026
Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232
Centers for Disease Control and Prevention. Diabetes and vision loss
Marso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844
Vilsbøll T, et al. Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-897
Leinung M, Patel N, Bettadahalli S, Paika MK, et al. Benefits of short-term professional continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013
Campbell UB, et al. Acute NAION and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12(1):139-151

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Ozempic #Mounjaro #Wegovy #ObesityMedicine

Most people think GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound are just for weight loss. The research tells a much bigger story. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine, with more than 15 years as a hospitalist. In this video I count down 12 evidence-graded health benefits of GLP-1 medications beyond the scale, plus a bonus from the newest cancer research.

You'll learn what the major trials show about your heart, liver, kidneys, blood pressure, sleep apnea, inflammation, alcohol cravings, joint pain and blood sugar. I also cover what the latest Alzheimer's trials actually found. Stay for number 1: a major analysis of the SELECT trial found that about two-thirds of the heart protection wasn't explained by weight loss.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

TIMESTAMPS
0:00 Why GLP-1s are about more than weight loss
1:05 Who I am and why this matters
1:56 #12 Blood pressure and blood fats
2:42 #11 Less joint pain, more mobility
3:52 #10 Fewer alcohol cravings
5:00 #9 A healthier liver
5:50 #8 Brain health: the honest version
6:55 How to protect muscle on a GLP-1 + Masterclass
8:42 #7 Sleep apnea and deeper sleep
9:40 #6 Fewer medications and diabetes prevention
10:35 BONUS: GLP-1s and cancer, the newest research
11:38 Free GLP-1 Diet Cookbook
12:03 #5 Quieter food noise and steadier blood sugar
12:57 #4 Protecting your kidneys
13:46 #3 Blood sugar and diabetes control
14:35 #2 Cooling down inflammation
15:27 #1 Protecting your heart and blood vessels

REFERENCES

Deanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements (SELECT analysis). Lancet. 2025. PMID: 41138739
Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002
Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure. Lancet. 2021;397:1625-1636
Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). N Engl J Med. 2024;391:1573-1583
Eli Lilly. Retatrutide TRIUMPH-4 topline results (press release, Dec 11, 2025; not yet peer-reviewed). https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
Kosiborod MN, et al. Semaglutide in HFpEF and obesity (STEP-HFpEF). N Engl J Med. 2023;389:1069-1084
Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder. JAMA Psychiatry. 2025;82(4):395-405
Klausen MK, et al. Once-weekly semaglutide vs placebo in alcohol use disorder and comorbid obesity. Lancet. 2026. PMID: 42070571
Younossi ZM, et al. The global epidemiology of NAFLD and NASH. Hepatology. 2023;77(4):1335-1347
Sanyal AJ, et al. Phase 3 trial of semaglutide in MASH (ESSENCE). N Engl J Med. 2025;392:2089-2099
Wang W, et al. Semaglutide and first-time diagnosis of Alzheimer's disease in type 2 diabetes. Alzheimers Dement. 2024;20(12):8661-8672
evoke and evoke+ Investigators. Oral semaglutide in early-stage symptomatic Alzheimer's disease. Lancet. 2026
Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined (S-LITE). N Engl J Med. 2021;384:1719-1730
Heymsfield SB, Aronne LJ, et al. Bimagrumab plus semaglutide for obesity (BELIEVE). Nat Med. 2026. https://www.nature.com/articles/s41591-026-04204-0
Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205
Jastreboff AM, et al. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 3 years). N Engl J Med. 2025;392:958-971
Lauby-Secretan B, et al. Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794-798
(complete list available upon request)

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Mounjaro #Tirzepatide #GLP1 #WeightLoss #obesitymedicine 

Why do two people on the same Mounjaro dose get completely different results? In this video, I break down a study of more than 3,000 people with type 2 diabetes from the SURPASS 1–4 trials. It looked at who is most likely to lose 15% or more of their body weight on tirzepatide (Mounjaro / Zepbound), and why.

You'll learn the 7 factors that predicted the biggest weight loss. Several of them are things you can change, sometimes before your first injection. I also cover what newer research says about Ozempic and Wegovy, why real-world results are lower than trial results, and the 6-month check-in that tells you whether you're on track.

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

TIMESTAMPS
0:00 Same drug, very different results
1:15 Mounjaro vs Zepbound vs Ozempic explained
2:19 What the SURPASS study measured
3:32 Factor 1: Sex
4:36 Factor 2: Age (and muscle loss)
6:32 Factor 3: Your starting blood sugar
8:36 Factor 4: Your cholesterol
9:32 GLP-1 Masterclass
10:12 Factor 5: Your other medications
11:41 Factor 6: Dose
12:34 Factor 7: Race and ethnicity
13:29 Surprise: starting weight didn't matter
13:58 Does this apply to Ozempic and Wegovy?
15:26 The limits of this research
16:36 7 steps to improve your odds
19:52 Free GLP-1 Diet Cookbook + what's next

REFERENCES

Małecki MT, Batterham RL, Sattar N, et al. Predictors of ≥15% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1–4. Diabetes Care. 2023;46(12):2292-2299. doi:10.2337/dc23-1135
Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36.
Aronne LJ, Horn DB, Kokkinos AD, et al. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026;139(7):913-921. doi:10.1016/j.amjmed.2026.03.010
Powell W, Song X, Mohamed Y, et al. Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data. Obesity (Silver Spring). 2023;31(10):2482-2492. doi:10.1002/oby.23859
Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729.
Sattar N, Frühbeck G, Andreelli F, et al. Weight reduction with tirzepatide varied meaningfully by baseline HbA1c category in adults with overweight or obesity and type 2 diabetes in SURMOUNT-2. Diabetes Care. 2025;48(11):e136-e137. doi:10.2337/dc25-1442
Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024.
Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S-1329S.
Mechanick JI, Butsch WS, Christensen SM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025;26(1):e13841.
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.
⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Ozempic #Zepbound #Wegovy #weightloss 

Losing weight on Wegovy, Ozempic, Zepbound, or Mounjaro? What you eat while you're on it matters more than most people realize. In this video, board-certified internal medicine and obesity medicine physician Dr. Mohammed Paika breaks down the 3 nutrition gaps that show up again and again in GLP-1 patients — protein, fiber, and fluids — and the 10 foods that address them, backed by real research on muscle preservation, gut health, and the GLP-1 pathway itself.

You'll learn why eating less doesn't automatically mean eating well, what the research says about muscle loss on semaglutide and tirzepatide, and exactly which foods to prioritize so you protect your muscle, support your gut, and get more out of your medication — not just a smaller number on the scale.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

Timestamps
0:00 Intro — The Mistake That's Sabotaging Your GLP-1 Results
2:03 Why What You Eat Matters More Than Ever
5:17 The 3 Nutrition Gaps on GLP-1 Medications
7:33 #1 Oats
8:55 #2 Turkey Breast
10:18 #3 Tofu & Edamame
11:35 #4 Tuna & Shrimp
12:44 #5 Quinoa
13:49 #6 Chia Seeds & Flaxseed
15:50 #7 Sweet Potatoes
17:07 #8 High-Protein Milk
18:31 #9 Kefir
20:08 #10 Watermelon, Citrus & Coconut Water
21:33 The One Rule That Ties It All Together
22:06 Final Thoughts

References

Johnson et al. "Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study." Frontiers in Nutrition, 2025;12.
Bikou A, et al. "A systematic review of the effect of semaglutide on lean mass: insights from clinical trials." Expert Opinion on Pharmacotherapy, 2024;25(5):611-619.
Look M, et al. "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study." Diabetes, Obesity and Metabolism, 2025.
Hirasawa T, et al. "Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120." Nature Medicine, 2005;11(1):90-94.
de Jong et al. "Dietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review." Frontiers in Endocrinology, 2026.
Tolhurst G, et al. "Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2." Diabetes, 2012;61(2):364-371.
Longland TA, et al. "Higher compared with lower dietary protein during an energy deficit..." American Journal of Clinical Nutrition, 2016.
Ogilvie AR, et al. "Higher protein intake during caloric restriction improves diet quality and attenuates loss of lean body mass." Obesity, 2022;30(11).
Nutrition figures throughout: USDA FoodData Central.

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.